Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol R Reed

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
JMIR Formative Research|February 10, 2022
An Integrated, Multimodal, Digital Health Solution for Chronic Obstructive Pulmonary Disease: Prospective Observational Pilot StudyBrian D Gelbman, Carol R Reed
Experimental Biology and Medicine (Maywood, N.J.)|October 14, 2008
The role of pharmacogenetics in treating central nervous system disordersMeeta Patnaik, Matthew J Renda, Maria C Athanasiou, et al.
Molecular Diagnosis & Therapy|June 15, 2006
Pharmacogenetic issues in thorough QT trialsRichard S Judson, Benjamin A Salisbury, Carol R Reed, et al.
The Journal of Sexual Medicine|December 11, 2012
The effect of vilazodone on sexual function during the treatment of major depressive disorderAnita H Clayton, Sidney H Kennedy, John B Edwards, et al.
The Journal of Clinical Psychiatry|March 17, 2009
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialKarl Rickels, Maria Athanasiou, Donald S Robinson, et al.
Journal of Clinical Psychopharmacology|August 27, 2011
A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderDonald S Robinson, Daniel K Kajdasz, Susan Gallipoli, et al.
Current Medical Research and Opinion|November 24, 2011
The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorderCarol R Reed, Daniel K Kajdasz, Heidi Whalen, et al.
Psychopharmacology Bulletin|October 15, 2016
The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive DisorderMichael Liebowitz, Harry A Croft, Daniel K Kajdasz, et al.
Heart Rhythm|May 3, 2008
Prevalence of early-onset atrial fibrillation in congenital long QT syndromeJonathan N Johnson, David J Tester, James Perry, et al.
Journal of the American College of Cardiology|October 17, 2009
The SLCO1B1*5 genetic variant is associated with statin-induced side effectsDeepak Voora, Svati H Shah, Ivan Spasojevic, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
JMIR Formative Research|February 10, 2022
An Integrated, Multimodal, Digital Health Solution for Chronic Obstructive Pulmonary Disease: Prospective Observational Pilot StudyBrian D Gelbman, Carol R Reed
Experimental Biology and Medicine (Maywood, N.J.)|October 14, 2008
The role of pharmacogenetics in treating central nervous system disordersMeeta Patnaik, Matthew J Renda, Maria C Athanasiou, et al.
Molecular Diagnosis & Therapy|June 15, 2006
Pharmacogenetic issues in thorough QT trialsRichard S Judson, Benjamin A Salisbury, Carol R Reed, et al.
The Journal of Sexual Medicine|December 11, 2012
The effect of vilazodone on sexual function during the treatment of major depressive disorderAnita H Clayton, Sidney H Kennedy, John B Edwards, et al.
The Journal of Clinical Psychiatry|March 17, 2009
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialKarl Rickels, Maria Athanasiou, Donald S Robinson, et al.
Journal of Clinical Psychopharmacology|August 27, 2011
A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorderDonald S Robinson, Daniel K Kajdasz, Susan Gallipoli, et al.
Current Medical Research and Opinion|November 24, 2011
The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorderCarol R Reed, Daniel K Kajdasz, Heidi Whalen, et al.
Psychopharmacology Bulletin|October 15, 2016
The Safety and Tolerability Profile of Vilazodone, A Novel Antidepressant for the Treatment of Major Depressive DisorderMichael Liebowitz, Harry A Croft, Daniel K Kajdasz, et al.
Heart Rhythm|May 3, 2008
Prevalence of early-onset atrial fibrillation in congenital long QT syndromeJonathan N Johnson, David J Tester, James Perry, et al.
Journal of the American College of Cardiology|October 17, 2009
The SLCO1B1*5 genetic variant is associated with statin-induced side effectsDeepak Voora, Svati H Shah, Ivan Spasojevic, et al.
Pageof 2